In an announcement Thursday, the biotech company said its treatment was 89.3 per cent effective at protecting 15,000 participants involved in a late-stage U.K. trial — half of which were infected with the U.K. variant of the virus.
A trial testing against the South African variant with 4,400 participants was 49.4 per cent effective, though preliminary results showed that only 25 were that of the new variant there.
“[This] is the first vaccine to demonstrate not only high clinical efficacy against COVID-19 but also significant clinical efficacy against both the rapidly emerging UK and South Africa variants,” said Novavax CEO Stanley C. Erck in a statement.
Canada sealed a deal last week with the company to purchase 52 million doses of the vaccine, with the option to purchase another 24 million.
More to come…
© 2021 Global News, a division of Corus Entertainment Inc.